Novo Nordisk has agreed to pay up to €1.165 billion ($1.3 billion) to license Swedish drug delivery company Nanexa's PharmaShell technology platform. The global exclusive deal covers use of the atomic layer deposition coating system for peptide-based drugs treating obesity, type 2 diabetes, and cardiometabolic conditions, with the technology designed to enable monthly or quarterly injection schedules for treatments like GLP-1 drugs.
Quwwaa is your AI news butler — a personalized brief and assistant for the stories you care about.
See more on Quwwaa — create a free account